The Clinical Relevance of the Clopidogrel–Proton Pump Inhibitor Interaction

  • Atif Mohammad
  • Emmanouil S. Brilakis
  • Rick A. Weideman
  • Bertis B. Little
  • Subhash Banerjee


Proton pump inhibitors are often prescribed concomitantly with clopidogrel and aspirin to patients post-percutaneous coronary interventions and/or an acute coronary syndrome to mitigate the risk of potential gastrointestinal bleeding, associated primarily with clopidogrel use. Over the last several years, there have been data both supporting and refuting a clopidogrel–proton pump inhibitor interaction. This review critically considers the current evidence and provides practical recommendations to healthcare providers.


Clopidogrel Proton pump inhibitor Percutaneous coronary intervention Drug interaction 


  1. 1.
    Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., & Casey, D. E., Jr. (2007). ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Journal of the American College of Cardiology, 50(7), e1–e157. Epub 2007/08/19.PubMedCrossRefGoogle Scholar
  2. 2.
    Bhatt, D. L., Scheiman, J., Abraham, N. S., Antman, E. M., Chan, F. K., & Furberg, C. D. (2008). ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation, 118(18), 1894–1909. Epub 2008/10/07.PubMedCrossRefGoogle Scholar
  3. 3.
    Shuldiner, A. R., O'Connell, J. R., Bliden, K. P., Gandhi, A., Ryan, K., & Horenstein, R. B. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA:The Journal of the American Medical Association, 302(8), 849–857. Epub 2009/08/27.PubMedCrossRefGoogle Scholar
  4. 4.
    Hulot, J. S., Bura, A., Villard, E., Azizi, M., Remones, V., & Goyenvalle, C. (2006). Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood, 108(7), 2244–2247. Epub 2006/06/15.PubMedCrossRefGoogle Scholar
  5. 5.
    Angiolillo, D. J., Gibson, C. M., Cheng, S., Ollier, C., Nicolas, O., & Bergougnan, L. (2011). Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clinical Pharmacology and Therapeutics, 89(1), 65–74. Epub 2010/09/17.PubMedCrossRefGoogle Scholar
  6. 6.
    O'Donoghue, M. L., Braunwald, E., Antman, E. M., Murphy, S. A., Bates, E. R., & Rozenman, Y. (2009). Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet, 374(9694), 989–997. Epub 2009/09/04.PubMedCrossRefGoogle Scholar
  7. 7.
    Bates, E. R., Lau, W. C., & Angiolillo, D. J. (2011). Clopidogrel–drug interactions. Journal of the American College of Cardiology, 57(11), 1251–1263. Epub 2011/03/12.PubMedCrossRefGoogle Scholar
  8. 8.
    Mega, J. L., Simon, T., Collet, J. P., Anderson, J. L., Antman, E. M., & Bliden, K. (2010). Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA: The Journal of the American Medical Association, 304(16), 1821–1830. doi:16. Epub 2010/10/28.CrossRefGoogle Scholar
  9. 9.
    Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., & Brandt, J. T. (2009). Cytochrome p-450 polymorphisms and response to clopidogrel. The New England Journal of Medicine, 360(4), 354–362. Epub 2008/12/25.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhang, H., Ragueneau-Majlessi, I., & Levy, R. H. (2009). Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition. Drug Metabolism Letters, 3(4), 287–289. Epub 2009/12/10.PubMedCrossRefGoogle Scholar
  11. 11.
    Sibbing, D., Morath, T., Stegherr, J., Braun, S., Vogt, W., & Hadamitzky, M. (2009). Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thrombosis and Haemostasis, 101(4), 714–719. Epub 2009/04/08.PubMedGoogle Scholar
  12. 12.
    Neubauer, H., Engelhardt, A., Krueger, J. C., Lask, S., Boergel, J., Muegge, A., et al. (2010). Pantoprazole does not influence the antiplatelet effect of clopidogrel—A whole blood aggregometry study after coronary stenting. Journal of Cardiovascular Pharmacology, 56, 91–97.PubMedCrossRefGoogle Scholar
  13. 13.
    Small, D. S., Farid, N. A., Payne, C. D., Weerakkody, G. J., Li, Y. G., & Brandt, J. T. (2008). Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Journal of Clinical Pharmacology, 48(4), 475–484. Epub 2008/02/28.PubMedCrossRefGoogle Scholar
  14. 14.
    Gurbel, P. A., Tantry, U. S., & Shuldiner, A. R. (2010). Letter by Gurbel et al. regarding article, “Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement”. Circulation, 122(14), e478. author reply e9. Epub 2010/10/06.PubMedCrossRefGoogle Scholar
  15. 15.
    Price, M. J., Tantry, U. S., & Gurbel, P. A. (2011). The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. Reviews in Cardiovascular Medicine, 12(1), 1–12. Epub 2011/05/07.PubMedGoogle Scholar
  16. 16.
    Munoz-Torrero, J. F., Escudero, D., Suarez, C., Sanclemente, C., Pascual, M. T., & Zamorano, J. (2011). Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry. Journal of Cardiovascular Pharmacology, 57(1), 13–19.PubMedCrossRefGoogle Scholar
  17. 17.
    Charlot, M., Grove, E. L., Hansen, P. R., Olesen, J. B., Ahlehoff, O., Selmer, C., et al. (2011). Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ, 342, d2690.PubMedCrossRefGoogle Scholar
  18. 18.
    Laine, L., & Hennekens, C. (2010). Proton pump inhibitor and clopidogrel interaction: fact or fiction? American Journal of Gastroenterology, 105(1), 34–41.PubMedCrossRefGoogle Scholar
  19. 19.
    Simon, T., Steg, P. G., Gilard, M., Blanchard, D., Bonello, L., Hanssen, M., et al. (2011). Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation, 123(5), 474–482.PubMedCrossRefGoogle Scholar
  20. 20.
    Juurlink, D. N., Gomes, T., Ko, D. T., Szmitko, P. E., Austin, P. C., & Tu, J. V. (2009). A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ: Canadian Medical Association Journal, 180(7), 713–718.PubMedCrossRefGoogle Scholar
  21. 21.
    Ho, P. M., Maddox, T. M., Wang, L., Fihn, S. D., Jesse, R. L., Peterson, E. D., et al. (2009). Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA: The Journal of the American Medical Association, 301(9), 937–944.CrossRefGoogle Scholar
  22. 22.
    Li, X. Q., Andersson, T. B., Ahlstrom, M., & Weidolf, L. (2004). Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metabolism and Disposition, 32(8), 821–827.PubMedCrossRefGoogle Scholar
  23. 23.
    Stockl, K. M., Le, L., Zakharyan, A., Harada, A. S., Solow, B. K., Addiego, J. E., et al. (2010). Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Archives of Internal Medicine, 170(8), 704–710.PubMedCrossRefGoogle Scholar
  24. 24.
    Kreutz, R. P., Stanek, E. J., Aubert, R., Yao, J., Breall, J. A., Desta, Z., et al. (2010). Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy, 30(8), 787–796.PubMedCrossRefGoogle Scholar
  25. 25.
    Ray, W. A., Murray, K. T., Griffin, M. R., Chung, C. P., Smalley, W. E., Hall, K., et al. (2010). Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Annals of Internal Medicine, 152(6), 337–345.PubMedGoogle Scholar
  26. 26.
    O'Donoghue, M., Antman, E. M., Braunwald, E., Murphy, S. A., Steg, P. G., Finkelstein, A., et al. (2009). The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology, 54(8), 678–685.PubMedCrossRefGoogle Scholar
  27. 27.
    Bhatt, D. L., Cryer, B. L., Contant, C. F., Cohen, M., Lanas, A., Schnitzer, T. J., et al. (2010). Clopidogrel with or without omeprazole in coronary artery disease. The New England Journal of Medicine, 363(20), 1909–1917.PubMedCrossRefGoogle Scholar
  28. 28.
    Depta, J. P., & Bhatt, D. L. (2010). Omeprazole and clopidogrel: Should clinicians be worried? Cleveland Clinic Journal of Medicine, 77(2), 113–116.PubMedCrossRefGoogle Scholar
  29. 29.
    Gurbel, P. A., & Tantry, U. S. (2011). Antiplatelet therapy: Clopidogrel–PPIs interaction, an ongoing controversy. Nature Reviews Cardiology, 8(1), 7–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Banerjee, S., Weideman, R. A., Weideman, M. W., Little, B. B., Kelly, K. C., Gunter, J. T., et al. (2011). Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. The American Journal of Cardiology, 107(6), 871–878.PubMedCrossRefGoogle Scholar
  31. 31.
    Ferreiro, J. L., Ueno, M., Tomasello, S. D., Capodanno, D., Desai, B., Dharmashankar, K., et al. (2011). Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Circulation. Cardiovascular Interventions, 4(3), 273–279.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC (outside the USA) 2012

Authors and Affiliations

  • Atif Mohammad
    • 1
    • 2
  • Emmanouil S. Brilakis
    • 1
    • 2
  • Rick A. Weideman
    • 1
  • Bertis B. Little
    • 1
    • 3
  • Subhash Banerjee
    • 1
    • 2
  1. 1.VA North Texas Health Care SystemDallasUSA
  2. 2.University of Texas Southwestern, Medical CenterDallasUSA
  3. 3.Tarleton State UniversityStephenvilleUSA

Personalised recommendations